Other News To Note
Cleveland BioLabs Inc., of Buffalo, N.Y., published results in the Journal of Immunology showing efficacy of entolimod (CBLB502) against graft-vs.-tumor activity in allogeneic bone marrow transplantation in mouse models.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST